Q123 has been an active quarter for Scandion Oncology with completion of the Phase 1b PANTAX (dose-finding) study and management’s decision to expand the scope of SCO-101 into acute myeloid leukaemia (AML). With many upcoming catalysts, including an update on AML preclinical work in H223, top-line results for CORIST part 3 in H223, and full top-line data for PANTAX by H124, if favourable, we expect material progression of the company’s pipeline. Scandion reported an operating loss of DKK12.0m in...
Scandion Oncology has announced that the Phase Ib PANTAX trial has concluded and reached its primary endpoint. This study (n=22) evaluated SCO-101, the company’s lead asset, as an add-on therapy for patients with advanced pancreatic cancer (PC). SCO-101, in combination with the chemotherapy agents gemcitabine and nab-paclitaxel, demonstrated a favourable safety and tolerability profile and a maximum tolerated dose (MTD) was established at 200mg for six consecutive days every two weeks. Managemen...
In the recent management conference call to summarise the FY22 results, Scandion Oncology announced plans to expand SCO-101, its lead asset, into acute myeloid leukaemia (AML). The company plans to share certain details on the preclinical data package in H223, which we view as a significant catalyst, provided the data continue to be supportive. SCO-101 is also progressing as planned in the Phase II CORIST trial in metastatic colorectal cancer (mCRC), with readouts expected in Q323, and in the Ph...
Scandion’s Q422 and FY22 results highlighted the significance of the upcoming year, with key clinical milestones expected for its lead asset SCO-101. The first of these comes in the form of top-line readouts from the Phase Ib PANTAX study in pancreatic cancer (PC), which is expected in H123. These will be closely followed by top-line results from part 3 of the Phase IIb CORIST study in metastatic colorectal cancer (mCRC), expected in Q323. Management has communicated that patient recruitment in ...
Scandion Oncology has announced the appointment of Francois Martelet, MD, as CEO, effective from 2 January 2023, when he will take over from acting CEO and CFO Johnny Stilou. Francois brings more than 30 years of pharmaceutical industry experience to Scandion, and will lead the development of Scandion’s chemotherapy sensitising drug SCO-101 in colorectal and pancreatic cancer. Previously, Francois held a number of biotech CEO positions and has extensive leadership experience at large pharmaceuti...
Scandion’s Q322 results provided an update on management’s continued commitment to execute on SCO-101’s clinical development strategy. Q322 operating losses amounted to DKK23.6m, largely driven by R&D expenses of DKK18.9m, with a net cash outflow from operations of DKK34.4m. With the initiation of CORIST part 3 in October, we now expect FY22 operating losses to increase to DKK86.5m (DKK65.2m previously). The net cash balance at end-Q322 stood at DKK91.4m (no debt) which, given current cash burn ...
Scandion Oncology has announced that the first patient in part 3 of the Phase II CORIST trial has been dosed. The CORIST development programme is investigating the use of the company’s chemotherapy add-on, SCO-101, in combination with FOLFIRI in metastatic colorectal cancer (mCRC). Importantly, part 3 will expand the patient population to include those harbouring RAS mutations (c 50% of patients) and will investigate optimised dosing schedules based on findings from CORIST part 2. The initiation...
Top-line results from part 2 of the Phase II CORIST trial in metastatic colorectal cancer (mCRC) were disappointing for Scandion, as the SCO-101/FOLFIRI combination failed to reach the 30% tumour reduction threshold. Despite this, SCO-101 did show indications of efficacy and the company intends to begin enrolment for CORIST part 3 in Q322, which will investigate a new dosing regimen in a larger patient population to fully evaluate SCO-101’s utility. We continue to estimate a cash runway for the ...
Scandion Oncology has announced top-line data from part 2 of the Phase II CORIST trial, investigating the company’s sole clinical asset, SCO-101, as a treatment for chemotherapy resistant metastatic colorectal cancer (mCRC). The results confirm the safety and tolerability of SCO-101 in combination with FOLFIRI; however, the drug did not meet the 30% reduction in tumour size threshold required for clinical proof-of-concept (PoC). The company notes that tumour reductions have been seen in some pat...
Scandion Oncology is approaching a major inflection point as results from the Phase II CORIST trial of the company’s lead asset, SCO-101, in metastatic colorectal cancer, are expected in Q322. In addition, top-line data from the extended Phase Ib PANTAX study in pancreatic cancer are expected in H123 (previously Q322). In H122, R&D related expenses rose to DKK33.0m, from DKK20.4m in H121, as patient enrolment continued for CORIST and PANTAX. In July 2022, Scandion completed a rights issue, which...
Scandion Oncology has received approval to initiate part 3 of its Phase II CORIST trial investigating SCO-101 for the treatment of metastatic colorectal cancer (mCRC). Part 3 is an expansion of the trial to evaluate the efficacy of SCO-101 in combination with FOLFIRI in both wild-type RAS (wtRAS) and mutant-RAS patient populations. Part 2 of the trial, which is ongoing, is evaluating wtRAS patients only. With c 44% of mCRC patients possessing the RAS mutation, we believe the pursuit of this new ...
Scandion Oncology has announced the extension of dose-escalation in the Phase Ib PANTAX trial, investigating the company’s add-on chemotherapy, SCO-101, in the treatment of metastatic pancreatic cancer (mPC). The observation of better-than-expected tolerability in patients has led Scandion to now pursue higher dosing than previously expected. As a result, top-line data from PANTAX are now expected in H123 (previously Q222). We view this as a positive development for Scandion, as the primary endp...
Edison Investment Research Limited Edison Investment Research Limited: Scandion Oncology (SCOL): Initiation - Chemotherapy overcoming drug resistance 21-Jun-2022 / 07:00 GMT/BST London, UK, 21 June 2022 Scandion Oncology (SCOL): Initiation - Chemotherapy overcoming drug resistance Scandion Oncology is a Danish biotechnology company that specialises in developing drugs to reverse chemotherapy resistance. Its lead asset, SCO-101, is being investigated as an add-on therapy to existing treatments in metastatic colorectal cancer (mCRC) and unresectable pancreatic cancer (PC). Man...
Scandion Oncology is a Danish biotechnology company that specialises in developing drugs to reverse chemotherapy resistance. Its lead asset, SCO-101, is being investigated as an add-on therapy to existing treatments in metastatic colorectal cancer (mCRC) and unresectable pancreatic cancer (PC). Management’s clinical programme is spearheaded by the Phase II CORIST study in FOLFIRI-resistant mCRC, from which we expect crucial proof-of-concept results in Q322. The company is also pursuing the Phase...
Scandion Oncology A/S (SCOL: FNSE) is a Denmark-based biotechnology company focused on developing drugs to treat cancers that have developed resistance to existing medical protocols. SCOL targets the resistance of cancer drugs for various treatments including chemotherapy, anti-hormonal therapy and immunotherapy. The company’s lead drug candidate, SCO-101 is in Phase Ib (PANTAX) and Phase II (CORIST) clinical trial. Important to note that, there are currently no drugs in the market targeting can...
Scandion Oncology is a biotechnology company focused on the development of therapies to alleviate drug resistance in prevalent cancers. Its most advanced clinical asset, SCO-101, acts via a dual mechanism to sensitise resistant cells to treatment. Scandion aims to target resistant metastatic colorectal cancer (mCRC) and pancreatic cancer with SCO-101. Part 1 of the Phase II trial, CORIST, in mCRC identified a tolerated dose and a good safety profile in July 2021. The proof-of-concept part 2 stud...
Scandion Oncology is a biotechnology company focused on the development of therapies to alleviate drug resistance in prevalent cancers. Its most advanced clinical asset, SCO-101, acts via a dual mechanism to sensitise resistant cells to treatment. Scandion aims to target resistant metastatic colorectal cancer (mCRC) and pancreatic cancer with SCO-101. Part 1 of the Phase II trial, CORIST, in mCRC identified a tolerated dose and a good safety profile in July 2021. The proof-of-concept part 2 stud...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.